GCG and Parkinson disease: GLP‐1 RA treatment was found to significantly lower incidences of dementia (risk difference (RD): −0.010), Alzheimer's disease (RD: −0.003), Parkinson's disease (RD: −0.002), pancreatic cancer (RD: −0.003), systemic lupus erythematosus (RD: −0.001) and systemic sclerosis (RD: −0.000) with p < 0.001 for all.